Acrodermatitis chronica atrophicans epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(6 intermediate revisions by the same user not shown)
Line 7: Line 7:
{{CMG}}; {{AE}} {{Anahita}}
{{CMG}}; {{AE}} {{Anahita}}
==Overview==
==Overview==
[[Acrodermatitis chronica atrophicans]] is a rare [[disease]]. The [[prevalence]] of [[acrodermatitis chronica atrophicans]] is estimated to include 10% of cases with [[lyme disease]] in Europe. The [[incidence]] of [[acrodermatitis chronica atrophicans]] increases with [[aging|age]] and commonly affects individuals in range of 40 to 70 years old with a [[median]] of 64 years old. However there are few [[case report|case reports]] on [[child|children]] who are [[diagnosis|diagnosed]] with [[acrodermatitis chronica atrophicans]]. [[Acrodermatitis chronica atrophicans]] affects [[female|women]] more than [[male|men]]. The majority of [[acrodermatitis chronica atrophicans]] cases are reported in northern, central and eastern Europe (most commonly in countries bordering the Baltic Sea). Lately few cases of [[acrodermatitis chronica atrophicans]] have been reported in the United States and Canada.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*Only 10% of [[Lyme disease|lyme disease]] cases in European population have been presented with [[arodermatitis chronica atrophicans]]. <ref name="pmid20540415">{{cite journal| author=Smetanick MT, Zellis SL, Ermolovich T| title=Acrodermatitis chronica atrophicans: a case report and review of the literature. | journal=Cutis | year= 2010 | volume= 85 | issue= 5 | pages= 247-52 | pmid=20540415 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20540415  }} </ref>
*Only 10% of [[Lyme disease|lyme disease]] cases in European population have been presented with [[arodermatitis chronica atrophicans]]. <ref name="pmid20540415">{{cite journal| author=Smetanick MT, Zellis SL, Ermolovich T| title=Acrodermatitis chronica atrophicans: a case report and review of the literature. | journal=Cutis | year= 2010 | volume= 85 | issue= 5 | pages= 247-52 | pmid=20540415 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20540415  }} </ref>


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The [[prevalence]] of [[acrodermatitis chronica atrophicans]] is estimated to include 10% of cases with [[lyme disease]] in Europe.<ref name="pmid33085436">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume= | issue=  | pages=  | pmid=33085436 | doi= | pmc= | url= }} </ref>
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
 
===Case-fatality rate/Mortality rate===
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*The [[incidence]] of [[acrodermatitis chronica atrophicans]] increases with [[aging|age]]. <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref>
*The [[incidence]] of [[acrodermatitis chronica atrophicans]] increases with [[aging|age]]. <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref>
*[[Acrodermatitis chronica atrophicans]] commonly affects individuals in range of 40 to 70 years old.<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref>  
*[[Acrodermatitis chronica atrophicans]] commonly affects individuals in range of 40 to 70 years old.<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref>  
*There are few [[case report|case reports]] on [[child|children]] who are [[diagnosis|diagnosed]] with [[acrodermatitis chronica atrophicans]].
*There are few [[case report|case reports]] on [[child|children]] who are [[diagnosis|diagnosed]] with [[acrodermatitis chronica atrophicans]].<ref name="NadalGundelfinger1988">{{cite journal|last1=Nadal|first1=D|last2=Gundelfinger|first2=R|last3=Flueler|first3=U|last4=Boltshauser|first4=E|title=Acrodermatitis chronica atrophicans.|journal=Archives of Disease in Childhood|volume=63|issue=1|year=1988|pages=72–74|issn=0003-9888|doi=10.1136/adc.63.1.72}}</ref>
*In a study done on 693 [[patients]] with [[acrodermatitis chronica atrophicans]] [[median]] [[Ageing|age]] of [[disease]] has been estimated 64 years old. <ref name="pmid33550695">{{cite journal| author=Ogrinc K, Maraspin V, Lusa L, Cerar Kišek T, Ružić-Sabljić E, Strle F| title=Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients. | journal=J Intern Med | year= 2021 | volume=  | issue=  | pages=  | pmid=33550695 | doi=10.1111/joim.13266 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33550695  }} </ref>
*In a study done on 693 [[patients]] with [[acrodermatitis chronica atrophicans]] [[median]] [[Ageing|age]] of [[disease]] has been estimated 64 years old. <ref name="pmid33550695">{{cite journal| author=Ogrinc K, Maraspin V, Lusa L, Cerar Kišek T, Ružić-Sabljić E, Strle F| title=Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients. | journal=J Intern Med | year= 2021 | volume=  | issue=  | pages=  | pmid=33550695 | doi=10.1111/joim.13266 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33550695  }} </ref>


===Race===
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*[[Acrodermatitis chronica atrophicans]] affects [[female|women]] more than [[male|men]].<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref>
*[[Acrodermatitis chronica atrophicans]] affects [[female|women]] more than [[male|men]].<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref><ref name="pmid33085436">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume=  | issue=  | pages=  | pmid=33085436 | doi= | pmc= | url= }} </ref>
*Based on several studies [[female]] predominance has been reported approximately 65-80 % in [[acrodermatitis chronica atrophicans]] [[patient]].<ref name="pmid18140373">{{cite journal| author=THYRESSON N| title=The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer). | journal=Acta Derm Venereol | year= 1949 | volume= 29 | issue= 6 | pages= 572-621 | pmid=18140373 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18140373  }} </ref><ref name="pmid3577484">{{cite journal| author=Asbrink E, Hovmark A, Olsson I| title=Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. | journal=Zentralbl Bakteriol Mikrobiol Hyg A | year= 1986 | volume= 263 | issue= 1-2 | pages= 253-61 | pmid=3577484 | doi=10.1016/s0176-6724(86)80128-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3577484  }} </ref><ref name="pmid3056202">{{cite journal| author=Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B | display-authors=etal| title=Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. | journal=Ann N Y Acad Sci | year= 1988 | volume= 539 | issue=  | pages= 324-45 | pmid=3056202 | doi=10.1111/j.1749-6632.1988.tb31867.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3056202  }} </ref>
*Based on several studies [[female]] predominance has been reported approximately 65-80 % in [[acrodermatitis chronica atrophicans]] [[patient]].<ref name="pmid18140373">{{cite journal| author=THYRESSON N| title=The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer). | journal=Acta Derm Venereol | year= 1949 | volume= 29 | issue= 6 | pages= 572-621 | pmid=18140373 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18140373  }} </ref><ref name="pmid3577484">{{cite journal| author=Asbrink E, Hovmark A, Olsson I| title=Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. | journal=Zentralbl Bakteriol Mikrobiol Hyg A | year= 1986 | volume= 263 | issue= 1-2 | pages= 253-61 | pmid=3577484 | doi=10.1016/s0176-6724(86)80128-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3577484  }} </ref><ref name="pmid3056202">{{cite journal| author=Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B | display-authors=etal| title=Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. | journal=Ann N Y Acad Sci | year= 1988 | volume= 539 | issue=  | pages= 324-45 | pmid=3056202 | doi=10.1111/j.1749-6632.1988.tb31867.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3056202  }} </ref>


===Region===
===Region===
*The majority of [[acrodermatitis chronica atrophicans]] cases are reported in northern, central and eastern Europe. <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref><ref name="pmid8221518">{{cite journal| author=Asbrink E| title=Acrodermatitis chronica atrophicans. | journal=Clin Dermatol | year= 1993 | volume= 11 | issue= 3 | pages= 369-75 | pmid=8221518 | doi=10.1016/0738-081x(93)90092-q | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8221518  }} </ref>
*The majority of [[acrodermatitis chronica atrophicans]] cases are reported in northern, central and eastern Europe (most commonly in countries bordering the Baltic Sea).<ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref><ref name="pmid8221518">{{cite journal| author=Asbrink E| title=Acrodermatitis chronica atrophicans. | journal=Clin Dermatol | year= 1993 | volume= 11 | issue= 3 | pages= 369-75 | pmid=8221518 | doi=10.1016/0738-081x(93)90092-q | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8221518 }} </ref><ref name="pmid32512846">{{cite journal| author=Scott JD| title=Presentation of Acrodermatitis Chronica Atrophicans Rashes on Lyme Disease Patients in Canada. | journal=Healthcare (Basel) | year= 2020 | volume= 8 | issue= 2 | pages=  | pmid=32512846 | doi=10.3390/healthcare8020157 | pmc=7349802 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32512846 }} </ref>
*Lately few cases of [[acrodermatitis chronica atrophicans]] have been reported in the United States which were associated to [[Lyme disease]] (besides European immigrants). <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153  }} </ref>
*Lately few cases of [[acrodermatitis chronica atrophicans]] have been reported in the United States which were associated to [[Lyme disease]] (besides European immigrants). <ref name="pmid30311153">{{cite journal| author=Khalili M, Wong RJ| title=Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. | journal=Dig Dis Sci | year= 2018 | volume= 63 | issue= 12 | pages= 3250-3252 | pmid=30311153 | doi=10.1007/s10620-018-5316-9 | pmc=6436636 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30311153 }} </ref><ref name="pmid33550695">{{cite journal| author=Ogrinc K, Maraspin V, Lusa L, Cerar Kišek T, Ružić-Sabljić E, Strle F| title=Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients. | journal=J Intern Med | year= 2021 | volume=  | issue=  | pages=  | pmid=33550695 | doi=10.1111/joim.13266 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33550695  }} </ref>
*Few cases have been observed in Canada recently.<ref name="pmid32512846">{{cite journal| author=Scott JD| title=Presentation of Acrodermatitis Chronica Atrophicans Rashes on Lyme Disease Patients in Canada. | journal=Healthcare (Basel) | year= 2020 | volume= 8 | issue= 2 | pages=  | pmid=32512846 | doi=10.3390/healthcare8020157 | pmc=7349802 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32512846 }} </ref>


==References==
==References==

Latest revision as of 11:06, 16 June 2021

Acrodermatitis chronica atrophicans Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acrodermatitis chronica atrophicans from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans epidemiology and demographics

CDC on Acrodermatitis chronica atrophicans epidemiology and demographics

Acrodermatitis chronica atrophicans epidemiology and demographics in the news

Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Acrodermatitis chronica atrophicans epidemiology and demographics


Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans epidemiology and demographics

CDC on Acrodermatitis chronica atrophicans epidemiology and demographics

Acrodermatitis chronica atrophicans epidemiology and demographics in the news

Blogs on Acrodermatitis chronica atrophicans epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Acrodermatitis chronica atrophicans epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]

Overview

Acrodermatitis chronica atrophicans is a rare disease. The prevalence of acrodermatitis chronica atrophicans is estimated to include 10% of cases with lyme disease in Europe. The incidence of acrodermatitis chronica atrophicans increases with age and commonly affects individuals in range of 40 to 70 years old with a median of 64 years old. However there are few case reports on children who are diagnosed with acrodermatitis chronica atrophicans. Acrodermatitis chronica atrophicans affects women more than men. The majority of acrodermatitis chronica atrophicans cases are reported in northern, central and eastern Europe (most commonly in countries bordering the Baltic Sea). Lately few cases of acrodermatitis chronica atrophicans have been reported in the United States and Canada.

Epidemiology and Demographics

Incidence

Prevalence

Age

Gender

Region

References

  1. ↑ Smetanick MT, Zellis SL, Ermolovich T (2010). "Acrodermatitis chronica atrophicans: a case report and review of the literature". Cutis. 85 (5): 247–52. PMID 20540415.
  2. ↑ 2.0 2.1 "StatPearls". 2021. PMID 33085436 Check |pmid= value (help).
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Khalili M, Wong RJ (2018). "Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net". Dig Dis Sci. 63 (12): 3250–3252. doi:10.1007/s10620-018-5316-9. PMC 6436636. PMID 30311153.
  4. ↑ Nadal, D; Gundelfinger, R; Flueler, U; Boltshauser, E (1988). "Acrodermatitis chronica atrophicans". Archives of Disease in Childhood. 63 (1): 72–74. doi:10.1136/adc.63.1.72. ISSN 0003-9888.
  5. ↑ 5.0 5.1 Ogrinc K, Maraspin V, Lusa L, Cerar Kišek T, Ružić-Sabljić E, Strle F (2021). "Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients". J Intern Med. doi:10.1111/joim.13266. PMID 33550695 Check |pmid= value (help).
  6. ↑ THYRESSON N (1949). "The penicillin treatment of acrodermatitis atrophicans chronica (Herxheimer)". Acta Derm Venereol. 29 (6): 572–621. PMID 18140373.
  7. ↑ Asbrink E, Hovmark A, Olsson I (1986). "Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients". Zentralbl Bakteriol Mikrobiol Hyg A. 263 (1–2): 253–61. doi:10.1016/s0176-6724(86)80128-6. PMID 3577484.
  8. ↑ Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B; et al. (1988). "Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans". Ann N Y Acad Sci. 539: 324–45. doi:10.1111/j.1749-6632.1988.tb31867.x. PMID 3056202.
  9. ↑ Asbrink E (1993). "Acrodermatitis chronica atrophicans". Clin Dermatol. 11 (3): 369–75. doi:10.1016/0738-081x(93)90092-q. PMID 8221518.
  10. ↑ 10.0 10.1 Scott JD (2020). "Presentation of Acrodermatitis Chronica Atrophicans Rashes on Lyme Disease Patients in Canada". Healthcare (Basel). 8 (2). doi:10.3390/healthcare8020157. PMC 7349802 Check |pmc= value (help). PMID 32512846 Check |pmid= value (help).

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Acrodermatitis_chronica_atrophicans_epidemiology_and_demographics&oldid=1704363"